Skip to main content
Clinical Trials/EUCTR2014-004674-42-PL
EUCTR2014-004674-42-PL
Active, not recruiting
Phase 1

A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead Sponsored Chronic Hepatitis C Infection Trials

Gilead Sciences, Inc0 sites560 target enrollmentFebruary 12, 2020

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Gilead Sciences, Inc
Enrollment
560
Status
Active, not recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 12, 2020
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Subjects must meet all of the following inclusion criteria to be eligible for participation in this Registry:
  • 1\. Have previously participated in a Gilead\-sponsored chronic hepatitis C study as an adolescent or pediatric subject and received at least one Gilead HCV direct acting antiviral (DAA).
  • 2\. Parent or legal guardian able to provide written informed consent OR subject able to provide written informed consent prior to any study procedures and willing to comply with study requirements as determined by IRB/IEC/local requirements and Investigator’s discretion.
  • 3\. Subject able to provide written assent, if they have the ability to read and write, as determined by IRB/IEC/local requirements and Investigator’s discretion.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 560
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 50
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Subjects who meet any of the following exclusion criteria are not to be enrolled in this Registry.
  • 1\. Subject is currently receiving or plans to initiate a new course of hepatitis C therapy including any investigational drug or device during the course of the follow\-up Registry.
  • 2\. History of clinically\-significant illness or any other major medical disorder that may interfere with the subject follow\-up, assessments, or compliance with the protocol.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A long-term study to follow patients infected with chronic Hepatitis C who received a Gilead Hepatitis C treatment in a Gilead clinical trial
EUCTR2014-004674-42-BEGilead Sciences, Inc.300
Active, not recruiting
Phase 1
A long-term study to follow patients infected with chronic Hepatitis C who received a Gilead Hepatitis C treatment in a Gilead clinical trial
EUCTR2014-004674-42-GBGilead Sciences, Inc.560
Active, not recruiting
Phase 1
A long-term study to follow patients infected with chronic Hepatitis C who received a Gilead Hepatitis C treatment in a Gilead clinical trialChronic Hepatitis C virus infectionMedDRA version: 20.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2014-004674-42-ITGILEAD SCIENCES INCORPORATED300
Active, not recruiting
Phase 1
A long-term study to follow patients infected with chronic Hepatitis C who received a Gilead Hepatitis C treatment in a Gilead clinical trialChronic Hepatitis C virus infectionMedDRA version: 20.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2014-004674-42-DEGilead Sciences, Inc.560
Active, not recruiting
Phase 1
A long-term study to follow patients infected with chronic Hepatitis C who achieved a cure following treatment in a Gilead clinical trial.Genotype 1 Hepatitis C Virus InfectionMedDRA version: 14.1Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2011-000945-19-ESGilead Sciences Inc.740